Dr. Melissa A. Burgess
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
About Melissa A. Burgess
Education:
Obtained a BS in Biochemistry & Molecular Biology and Chemistry from Dickinson College in 2005.
Earned an MD from Drexel University College of Medicine in 2009.
Completed Internal Medicine Residency at the University of Pittsburgh, UPMC (2009-2012).
Finished Hematology/Oncology Fellowship at the University of Pittsburgh, UPMC (2012-2015), serving as Chief in 2014.
Experience:
Serves as Assistant Professor of Medicine at the University of Pittsburgh School of Medicine.
Acts as a Clinical and Translational Investigator in Sarcoma, with a focus on clinical trials.
Holds the position of Local Principal Investigator for several clinical trials, including SARC 028 and CITN-09.
Specializes in the treatment of soft tissue and bone sarcoma patients at the Hillman Cancer Center.
Area of expertise
Cancer
Melissa A. Burgess has run 13 trials for Cancer. Some of their research focus areas include:
Soft Tissue Sarcoma
Melissa A. Burgess has run 10 trials for Soft Tissue Sarcoma. Some of their research focus areas include:
Affiliated Hospitals
University Of Pittsburgh Cancer Institute (UPCI)
University Of Pittsburgh Medical Center
Clinical Trials Melissa A. Burgess is currently running
Atezolizumab +/− Selinexor
for Sarcoma
This trial is testing if atezolizumab alone or with selinexor can shrink tumors in patients with a rare type of cancer called alveolar soft part sarcoma. Atezolizumab boosts the immune system to fight cancer, and selinexor stops cancer cells from growing. The goal is to see if these treatments work better than the usual care.
Recruiting
1 award
Phase 2
Immunotherapy + Chemotherapy
for Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting
2 awards
Phase 3
10 criteria
More about Melissa A. Burgess
Clinical Trial Related
5 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Melissa A. Burgess has experience with
- Nivolumab
- Atezolizumab
- Doxorubicin
- Dacarbazine
- Placebo
- Pembrolizumab
Breakdown of trials Melissa A. Burgess has run
Cancer
Soft Tissue Sarcoma
Skin Cancer
Leiomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Melissa A. Burgess specialize in?
Melissa A. Burgess focuses on Cancer and Soft Tissue Sarcoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are EWSR1/ATF1 positive.
Is Melissa A. Burgess currently recruiting for clinical trials?
Yes, Melissa A. Burgess is currently recruiting for 4 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Melissa A. Burgess has studied deeply?
Yes, Melissa A. Burgess has studied treatments such as Nivolumab, Atezolizumab, Doxorubicin.
What is the best way to schedule an appointment with Melissa A. Burgess?
Apply for one of the trials that Melissa A. Burgess is conducting.
What is the office address of Melissa A. Burgess?
The office of Melissa A. Burgess is located at: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the University of Pittsburgh Cancer Institute (UPCI).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.